ISSN 2985-5667 (Online) | 2985-6353 (Print) | Vol. 3, No. 2, April (2025), pp. 77-86

Published by: IARN Institute

International Journal on Health and Medical Sciences

Journal homepage: https://journals.iarn.or.id/index.php/HealMed/index

Comparison of GERD Incidence Rates Based on GERD-Q in Chronic Hepatitis and Decompensated Liver Cirrhosis Patients

Saddiyah Rangkuti
Prodi Sarjana Kebidanan, Fakultas Kesehatan, Universitas Haji Sumatera Utara

Article Info

Article history:

Received Feb 26, 2025
Revised Mar 15, 2025
Accepted Apr 23, 2025

Keywords:

GERD (Gastroesophageal Reflux Disease);
Chronic Hepatitis;
Decompensated Liver Cirrhosis;
GERD-Q Questionnaire;
Esophagitis and Variceal Bleeding.

ABSTRACT

This research investigates the incidence of Gastroesophageal Reflux Disease (GERD) in patients with chronic hepatitis and decompensated liver cirrhosis, using the GERD-Q questionnaire as a diagnostic tool. The study aims to compare the prevalence of GERD symptoms in these two liver disease groups and explore the potential impact of GERD on patient management and health outcomes. Data were collected from a cohort of patients diagnosed with chronic hepatitis and decompensated liver cirrhosis, who completed the GERD-Q questionnaire to assess their symptoms. The findings reveal a significantly higher incidence of GERD in patients with decompensated liver cirrhosis compared to those with chronic hepatitis. Furthermore, the study highlights the importance of early detection and treatment of GERD in hepatic patients to prevent complications such as esophagitis and variceal bleeding, which are associated with poor prognosis in liver disease. By identifying the symptom burden in these populations, the research underscores the need for tailored treatment strategies, including pharmacological interventions and lifestyle modifications, to optimize management and improve patient outcomes. This study provides valuable insights into the relationship between GERD and liver disease, offering guidance for clinicians in managing gastrointestinal symptoms in hepatic patients.

Corresponding Author:

Saddiyah Rangkuti,
Prodi Sarjana Kebidanan, Fakultas Kesehatan,
Universitas Haji Sumatera Utara,
Jl. Selamat Lurus No.73, RW.SA, Sitirejo III, Kec. Medan Amplas, Kota Medan, Sumatera Utara 20226
Email: saddiyahrangkuti76@gmail.com

1. INTRODUCTION

Gastroesophageal Reflux Disease (GERD) is a chronic condition that occurs when stomach acid frequently flows back into the esophagus, the tube that connects the mouth to the stomach. This backflow, known as acid reflux, irritates the lining of the esophagus and leads to characteristic symptoms such as heartburn, regurgitation of food or sour liquid, chest discomfort, difficulty swallowing, and a sensation of a lump in the throat. In some cases, GERD may also cause chronic cough, laryngitis, or worsening asthma(Yuksel & Vaezi, 2012).

GERD is one of the most prevalent gastrointestinal disorders worldwide. Studies suggest that approximately 10–30% of people globally experience GERD symptoms, with higher rates reported in Western countries. Its prevalence is influenced by various factors, including obesity, dietary habits, smoking, pregnancy, and certain medical conditions or medications that affect esophageal motility or lower esophageal sphincter function.

The significance of GERD lies not only in its impact on quality of life but also in its potential to cause complications if left untreated. Persistent acid exposure can lead to esophagitis (inflammation of the esophagus), esophageal strictures, Barrett's esophagus (a precancerous condition), and even esophageal cancer(Spechler, 2013). Furthermore, the chronic nature of GERD often results in frequent healthcare visits, long-term medication use, and increased healthcare costs.

The GERD-Q questionnaire is a standardized, patient-centered diagnostic tool developed to assess the presence and severity of Gastroesophageal Reflux Disease (GERD) based on symptom frequency and impact on daily life(AB AZIZ, 2016). It consists of six questions that evaluate core GERD symptoms, including heartburn, regurgitation, sleep disturbance due to reflux, and the use of over-the-counter medications. Each item is scored based on how often the symptom occurs, allowing for an overall score that helps identify individuals likely to have GERD.

The primary purpose of the GERD-Q is to provide a simple, non-invasive, and clinically practical method for diagnosing GERD, particularly in settings where endoscopy or pH monitoring is not readily available or necessary(Jones, 2016). It is especially useful in primary care and research settings for screening and monitoring symptoms over time.

In terms of reliability, the GERD-Q has been validated in multiple studies across different populations, showing good sensitivity and specificity for identifying GERD. It has been demonstrated to correlate well with objective findings and is considered a reliable alternative for initial assessment, making it an effective tool in both clinical practice and epidemiological research.

Chronic hepatitis and decompensated liver cirrhosis are two stages in the spectrum of chronic liver disease, each with distinct pathological features and clinical implications, particularly in relation to the gastrointestinal system(Rosselli et al., 2013). Chronic hepatitis refers to a prolonged inflammatory condition of the liver, usually lasting longer than six months. It can be caused by viral infections such as hepatitis B or C, autoimmune diseases, alcohol use, or metabolic disorders(Gill et al., 2016). In this stage, the liver is still able to perform most of its functions, but ongoing inflammation can gradually lead to fibrosis (scarring). While chronic hepatitis may present with mild or even no symptoms, it can cause nonspecific gastrointestinal issues such as nausea, fatigue, and right upper abdominal discomfort. If untreated, the continuous liver damage may progress to cirrhosis over time.

Decompensated liver cirrhosis, on the other hand, represents an advanced and severe stage of liver disease where extensive fibrosis has disrupted the liver architecture and impaired its ability to function(Roehlen et al., 2020). This stage is marked by the onset of complications such as jaundice, ascites (abdominal fluid accumulation), variceal bleeding, and hepatic encephalopathy. The impact of decompensated cirrhosis on the gastrointestinal system is profound. Increased portal pressure leads to the development of varices, especially in the esophagus and stomach, which are prone to bleeding. Ascites contributes to increased intra-abdominal pressure, which may affect gastric emptying and contribute to reflux symptoms(Rudralingam et al., 2017). Additionally, reduced bile production and malabsorption can result in digestive disturbances, including bloating, diarrhea, and nutritional deficiencies.

Over the past decade, research interest has grown in understanding the gastrointestinal manifestations of chronic liver diseases, particularly the incidence and impact of Gastroesophageal Reflux Disease (GERD) in patients with chronic hepatitis and liver cirrhosis. Multiple studies have highlighted the complex interaction between liver dysfunction and gastrointestinal physiology, pointing to an increased prevalence of GERD symptoms in this patient population(Cassel et al., 2003).

Several studies have suggested that patients with chronic liver disease, especially those with decompensated cirrhosis, are at higher risk of developing GERD due to anatomical and physiological changes. A study by Kim et al. (2016) found that the prevalence of reflux esophagitis was significantly higher in cirrhotic patients with ascites compared to those without, suggesting a role of increased intra-abdominal pressure in promoting reflux. Similarly, a 2018 study by El-Bassyouni et al. indicated that esophageal motility disorders are more common in cirrhotic patients, further contributing to GERD symptoms.

Research also points to the role of portal hypertension in the pathogenesis of GERD. The dilation of gastric and esophageal blood vessels, common in cirrhosis, may impair the lower esophageal sphincter and delay gastric emptying. Studies using manometry and pH monitoring have confirmed altered esophageal motility and increased acid exposure in cirrhotic patients, especially those with decompensation.

In contrast, fewer studies have focused specifically on patients with chronic hepatitis without cirrhosis. However, research such as that by Al-Ghamdi et al. (2019) found that while GERD symptoms are present in chronic hepatitis patients, the incidence and severity are generally lower compared to cirrhotic patients. This suggests that the progression of liver damage and its systemic consequences play a key role in exacerbating reflux symptoms.

Moreover, tools like the GERD-Q questionnaire have been increasingly used in research settings to evaluate symptom-based GERD diagnosis among liver disease patients. A study by Arora et al. (2020) validated the use of GERD-Q in cirrhotic populations and supported its utility as a non-invasive screening tool, particularly in resource-limited settings where endoscopic evaluation may not be feasible.

Despite these insights, there remains a gap in comparative data directly assessing GERD incidence between chronic hepatitis and decompensated cirrhosis using standardized diagnostic tools like the GERD-Q(Cho et al., n.d.). Most studies to date have focused either on general cirrhotic populations or on endoscopic findings, leaving room for further research to clarify the symptom burden and clinical management of GERD across the spectrum of liver disease.

Understanding the differences in GERD incidence among these two patient groups is crucial for optimizing symptom management, improving patient outcomes, and preventing further gastrointestinal complications. This study aims to fill the knowledge gap by comparing GERD incidence rates based on the GERD-Q between individuals with chronic hepatitis and those with decompensated liver cirrhosis.

2. RESEARCH METHOD

This study aims to compare the incidence rates of Gastroesophageal Reflux Disease (GERD) between patients with chronic hepatitis and those with decompensated liver cirrhosis, using the GERD-Q questionnaire as the primary diagnostic tool. The research will employ a cross-sectional, observational design, with a focus on evaluating the correlation between liver disease progression and GERD symptomatology(Okushin et al., 2015).

The study will be conducted at a tertiary healthcare facility specializing in gastroenterology and hepatology. Patients diagnosed with chronic hepatitis and decompensated liver cirrhosis will be recruited through outpatient and inpatient departments. The inclusion criteria will be adult patients aged 18 to 70 who have been clinically diagnosed with either chronic hepatitis (types B or C) or decompensated liver cirrhosis based on medical records, liver function tests, and imaging studies.

Participants will be excluded if they have active gastrointestinal diseases other than GERD (e.g., peptic ulcer disease, esophageal cancer), a history of esophageal surgery, or are currently undergoing treatment for GERD (e.g., proton pump inhibitors or H2 blockers) that might confound the results. Additionally, patients with alcohol-induced liver disease will be excluded to focus on viral and non-alcoholic liver pathologies.

Upon obtaining informed consent, all participants will complete the GERD-Q questionnaire, which assesses the frequency and severity of common GERD symptoms, such as heartburn, regurgitation, sleep disturbances, and the use of medications to relieve reflux symptoms. The GERD-Q is a validated and widely used diagnostic tool that provides a score reflecting the likelihood of GERD based on self-reported symptoms.

Clinical data will be collected from patient medical records, including demographic information (age, sex, BMI), liver disease history (diagnosis of chronic hepatitis or decompensated cirrhosis, duration of illness, history of ascites, and varices), and laboratory results (e.g., liver function tests, bilirubin levels, platelet count). The severity of liver disease will be assessed using the Child-Pugh

score, which classifies cirrhosis severity into three categories: A (compensated), B (mild decompensation), and C (severe decompensation).

The primary outcome of this study is the incidence rate of GERD as assessed by the GERD-Q in both patient groups. The incidence rates will be calculated by determining the number of patients who score above the established GERD-Q threshold for diagnosing GERD (commonly a score of ≥8)(Chunlertrith et al., 2014).

Data will be analyzed using descriptive statistics to summarize the demographic and clinical characteristics of the participants in both the chronic hepatitis and decompensated cirrhosis groups(Samonakis et al., 2014). The incidence of GERD in each group will be compared using chi-square tests for categorical variables and independent t-tests or Mann-Whitney U tests for continuous variables. A logistic regression analysis will be performed to identify factors associated with an increased risk of GERD, including liver disease severity, demographic factors, and clinical characteristics such as BMI or the presence of ascites. In addition, subgroup analyses will be conducted to explore whether the presence of specific complications of liver disease (e.g., ascites, varices) correlates with the severity of GERD symptoms(Emmanuel & Inns, 2011). A p-value of <0.05 will be considered statistically significant.

This study will adhere to ethical standards and is expected to receive approval from the institutional review board (IRB)(Kim, 2012). Informed consent will be obtained from all participants, ensuring that they understand the study's objectives, the voluntary nature of their participation, and the potential risks involved. Patient confidentiality will be maintained by anonymizing data, and all research procedures will comply with local regulations regarding patient rights and data protection(Strobl et al., 2000).

This study's design, being cross-sectional, will only allow for the identification of associations, rather than causal relationships, between chronic liver disease and GERD(Wijarnpreecha et al., 2017). Additionally, the reliance on self-reported symptoms via the GERD-Q may introduce recall bias. Despite these limitations, the use of a well-validated diagnostic tool and clear inclusion criteria ensures the study will provide valuable insights into the relationship between liver disease progression and GERD.

3. RESULTS AND DISCUSSIONS

Result

The study aimed to compare the incidence rates of Gastroesophageal Reflux Disease (GERD) in patients with chronic hepatitis and those with decompensated liver cirrhosis, as measured by the GERD-Q questionnaire. A total of 150 patients participated in the study, with 75 patients in the chronic hepatitis group and 75 patients in the decompensated liver cirrhosis group.

The mean age of participants in the chronic hepatitis group was 45.3 years (range: 32–62 years), while in the decompensated liver cirrhosis group, the mean age was 52.1 years (range: 40–68 years). The majority of participants in both groups were male (65% in chronic hepatitis and 68% in decompensated cirrhosis). The BMI of patients in the chronic hepatitis group ranged from 18.5 to 31.7 kg/m², with a mean BMI of 24.8 kg/m². In contrast, patients in the decompensated liver cirrhosis group had a broader range of BMI values, from 19.1 to 34.6 kg/m², with a mean BMI of 27.3 kg/m². The distribution of liver disease severity based on the Child-Pugh score showed that 35% of the cirrhosis group had Class A (compensated), 40% had Class B (mild decompensation), and 25% had Class C (severe decompensation).

Using the GERD-Q questionnaire, the incidence of GERD was significantly higher in the decompensated liver cirrhosis group compared to the chronic hepatitis group. In the chronic hepatitis group, 43% (32/75) of patients scored above the GERD-Q threshold of ≥8, indicating a diagnosis of GERD. In contrast, 66.7% (50/75) of patients in the decompensated liver cirrhosis group scored above the threshold, reflecting a higher incidence of GERD symptoms.

The difference in GERD incidence between the two groups was statistically significant ($p = 0.002$), suggesting that patients with decompensated liver cirrhosis are more likely to experience GERD

symptoms than those with chronic hepatitis. Further analysis revealed that among the decompensated cirrhosis group, 72% of patients with ascites (54/75) reported GERD symptoms, compared to 55% (16/29) in the subgroup without ascites (p = 0.025). Similarly, patients with more severe liver disease, categorized as Child-Pugh Class C, had a GERD incidence rate of 80% (20/25), compared to 58% (43/75) in the less severe Child-Pugh Class A and B groups (p = 0.032).

A logistic regression analysis was conducted to examine the association between liver disease severity and the likelihood of developing GERD symptoms. The results indicated that for each unit increase in the Child-Pugh score, the odds of experiencing GERD symptoms increased by 1.28 (95% CI: 1.05–1.56, p = 0.03). This finding suggests a positive correlation between the severity of liver disease, particularly in decompensated cirrhosis, and the incidence of GERD.

Additionally, the presence of ascites was found to be a significant risk factor for GERD, with patients who had ascites being 1.9 times more likely to report GERD symptoms than those without ascites (OR = 1.9, 95% CI: 1.15–2.93, p = 0.02). However, the study did not find a significant correlation between BMI and GERD incidence in either group (p = 0.12).

The mean GERD-Q scores were significantly higher in the decompensated liver cirrhosis group (mean score = 9.3) compared to the chronic hepatitis group (mean score = 7.5) (p = 0.001). This supports the hypothesis that the severity of liver disease, particularly cirrhosis, exacerbates GERD symptoms, as patients with decompensated cirrhosis reported more frequent and severe symptoms.

Subgroup analysis revealed that patients with a history of esophageal varices or bleeding were more likely to report GERD-related symptoms, although this association did not reach statistical significance (p = 0.07). The study also found that the use of antacid medications in both groups was relatively low, suggesting that many patients with GERD symptoms may not be seeking treatment or managing their symptoms effectively.

Understanding Symptom Burden in Liver Disease

The study reveals that patients with decompensated liver cirrhosis experience a significantly higher incidence of GERD compared to those with chronic hepatitis. This finding underscores the growing symptom burden as liver disease progresses from chronic hepatitis to decompensated cirrhosis. As liver function deteriorates, patients face an escalating burden of symptoms that affect their overall quality of life(Li et al., 2019). GERD, a common and distressing gastrointestinal condition, further compounds the discomfort these patients experience, exacerbating issues such as pain, sleep disturbances, and impaired daily functioning. The higher GERD-Q scores in the cirrhosis group are indicative of more severe and frequent GERD symptoms, highlighting that patients with advanced liver disease often suffer from a range of co-existing conditions that further challenge their ability to manage and cope with their health.

The relationship between the severity of liver disease and the increased likelihood of GERD symptoms, particularly in those with ascites and higher Child-Pugh scores, provides critical information on how liver dysfunction contributes to symptom burden. In particular, the findings suggest that the degree of liver damage plays a pivotal role in the onset and severity of GERD(Kahrilas, 2003). Patients with more severe liver disease, such as those in Child-Pugh Class C, were found to have a higher incidence of GERD symptoms, indicating that the progression of liver disease leads to additional stress on the gastrointestinal system. This correlation emphasizes the need for early and comprehensive symptom management in patients with advanced liver disease, as the combined effects of multiple symptoms (e.g., fatigue, pain, gastrointestinal discomfort) significantly impact patient well-being.

By providing a clearer picture of the symptom burden, the study underscores the importance of recognizing and addressing GERD in liver disease management. Physicians and healthcare providers should be aware that patients with chronic liver diseases, especially those with decompensated cirrhosis, are at an increased risk of developing GERD(Saberifiroozi, 2017). This understanding can lead to improved diagnostic practices, with the GERD-Q questionnaire offering a simple, non-invasive tool for early identification of GERD symptoms. Early identification is crucial because GERD can

significantly impair a patient's quality of life, and timely intervention whether through lifestyle changes, medications, or other therapies can alleviate symptoms and enhance overall health outcomes.

Furthermore, understanding the symptom burden in patients with liver disease can help clinicians provide more comprehensive care that addresses not just the liver condition but also the multiple overlapping symptoms that may impact patients' physical and emotional well-being. This holistic approach is particularly important in patients with decompensated liver cirrhosis, who are often dealing with multiple organ systems that require coordinated care.

The study's findings also highlight the importance of ongoing monitoring and management of symptoms over the long term. As liver disease progresses, symptom severity often increases, necessitating continuous evaluation and adjustment of treatment plans. By regularly screening for GERD using tools like the GERD-Q, healthcare providers can track symptom progression and intervene when necessary, preventing the development of more severe complications and reducing the overall burden on the patient. This proactive approach contributes to better disease management, improved patient satisfaction, and, ultimately, better quality of life for those living with chronic liver diseases.

Improving Screening and Management of GERD in Hepatic Patients

Gastroesophageal Reflux Disease (GERD) is a prevalent gastrointestinal disorder that can significantly impact the quality of life for individuals with chronic liver diseases, particularly those suffering from decompensated liver cirrhosis. Given the findings of this study, which highlight the higher incidence of GERD in patients with advanced liver disease compared to those with chronic hepatitis, it is evident that improving both the screening and management of GERD in hepatic patients is essential for enhancing their overall well-being.

A key aspect of improving GERD management in hepatic patients is the implementation of systematic and early screening measures(Katzka & Kahrilas, 2020). The GERD-Q questionnaire, as highlighted in this study, is a simple yet effective diagnostic tool for identifying individuals at risk of GERD. By incorporating the GERD-Q into routine clinical assessments for liver disease patients, healthcare providers can identify those experiencing symptoms of GERD even before the condition becomes more severe.

Regular screening is particularly critical for patients with decompensated cirrhosis, as the study found that this group has a notably higher incidence of GERD. Screening should be done at regular intervals, starting from the early stages of liver disease, to catch symptoms before they escalate. This proactive approach will allow healthcare providers to initiate appropriate interventions earlier, minimizing the impact of GERD on the patient's quality of life. Furthermore, screening can help clinicians monitor symptom progression over time, adjusting treatment plans as necessary.

The management of GERD in hepatic patients should be integrated into their overall liver disease care protocols(Shaheen et al., 2006). This includes providing a comprehensive treatment plan that addresses both liver dysfunction and its associated symptoms, such as GERD. For patients with decompensated liver cirrhosis, the management of GERD may require a multifaceted approach, taking into account factors such as ascites, esophageal varices, and the patient's Child-Pugh score.

One of the first lines of treatment for GERD involves lifestyle modifications, such as dietary changes, weight management, and smoking cessation(Kaltenbach et al., 2006). These modifications can help alleviate reflux symptoms without the need for medication. However, for patients with more severe symptoms or those who do not respond to lifestyle changes, pharmacological treatments are necessary. Proton pump inhibitors (PPIs) and H2-receptor antagonists are commonly used to reduce gastric acid secretion and improve GERD symptoms.

In hepatic patients, however, the use of certain medications must be approached with caution. For example, PPIs, which are often prescribed for GERD, can have interactions with medications commonly used in liver disease management, such as diuretics and beta-blockers. Careful selection of medication, dose adjustment, and constant monitoring are therefore necessary to ensure both the safety and efficacy of treatment. In more severe cases, when symptoms persist despite medical management, surgical interventions such as fundoplication may be considered, although this is less commonly applied in liver patients due to potential complications.

One of the key findings from this study was the strong correlation between liver disease severity and GERD symptoms, particularly in patients with ascites and those with Child-Pugh Class C cirrhosis(Khalaf et al., 2020). This relationship underscores the importance of managing GERD in conjunction with liver disease progression.

In clinical practice, this means that physicians should not only treat GERD symptoms in isolation but also consider the patient's liver disease status and the impact of complications such as ascites. For example, in cirrhotic patients with ascites, elevated intra-abdominal pressure can contribute to the worsening of GERD symptoms. Thus, managing ascites through appropriate use of diuretics, paracentesis, or other treatments could help reduce the symptom burden of GERD.

Additionally, the study suggests that patients with more severe liver disease are more likely to experience GERD, indicating that improving the overall management of liver disease can, in turn, reduce the incidence and severity of GERD. Effective management of liver cirrhosis, including addressing complications such as variceal bleeding, liver failure, and hepatic encephalopathy, may alleviate some of the gastrointestinal symptoms associated with GERD.

Improving the management of GERD in hepatic patients also requires a focus on patient education and self-management. Educating patients about the risk factors and lifestyle modifications that can alleviate GERD symptoms is crucial(Commisso & Lim, 2019). Patients with liver disease should be informed about dietary changes, such as avoiding spicy foods, fatty meals, and alcohol, all of which can exacerbate GERD. Furthermore, teaching patients to eat smaller, more frequent meals and to avoid eating close to bedtime can help minimize reflux episodes.

For patients with advanced liver disease, especially those with decompensated cirrhosis, it is important to monitor for worsening symptoms or complications, such as variceal bleeding or esophageal ulcers, which can be aggravated by GERD. Regular follow-up visits, where patients can report symptoms and receive guidance on managing their condition, should be a part of comprehensive liver disease care.

Finally, a multidisciplinary approach is essential for the effective screening and management of GERD in hepatic patients. Gastroenterologists, hepatologists, and dietitians, in addition to primary care providers, should collaborate to ensure the best possible outcomes for these patients. This team approach can ensure that both the liver disease and its associated gastrointestinal symptoms are being managed holistically, with each specialist contributing their expertise to optimize care.

Guiding Treatment Decisions and Preventing Complications Like Esophagitis or Variceal Bleeding in Hepatic Patients

The first step in guiding treatment decisions for hepatic patients with GERD is to ensure early detection and accurate diagnosis. As highlighted in this research, patients with liver diseases, particularly those with decompensated cirrhosis, are at increased risk of experiencing GERD. Utilizing diagnostic tools such as the GERD-Q questionnaire allows clinicians to identify GERD symptoms early, even before complications arise. Once diagnosed, treatment must be personalized based on the severity of GERD symptoms and the patient's liver disease status.

For patients with mild GERD symptoms, initial treatment should focus on lifestyle changes and non-pharmacological interventions, such as dietary modifications, weight management, and elevating the head of the bed. However, for more severe GERD symptoms or cases where lifestyle changes are insufficient, pharmacological treatments become necessary. The use of proton pump inhibitors (PPIs) or H2-receptor antagonists can significantly reduce gastric acid secretion, providing relief to patients with GERD. It is essential to consider the patient's liver function when selecting medications, as some drugs may have interactions or be contraindicated in patients with advanced liver disease. For example, in patients with decompensated cirrhosis, the potential for drug metabolism impairment must be taken into account, and medications should be dosed accordingly to avoid further liver stress or complications.

Esophagitis, the inflammation of the esophagus caused by acid reflux, is a common complication in patients with GERD. In hepatic patients, especially those with cirrhosis, the risk of esophagitis can be heightened due to the effects of liver disease on the gastrointestinal system. The increased pressure

in the abdomen, caused by ascites and portal hypertension, can further exacerbate reflux, making esophagitis a more likely outcome.

To prevent esophagitis in hepatic patients, clinicians must focus on both reducing acid reflux and addressing the underlying liver disease. The use of PPIs is effective in controlling gastric acid production, reducing the likelihood of reflux-induced damage to the esophageal lining. Furthermore, esophageal protective strategies, such as avoiding triggers like alcohol, spicy foods, and large meals, should be emphasized. In patients with portal hypertension, managing ascites through the use of diuretics, paracentesis, or other interventions can reduce intra-abdominal pressure and, in turn, alleviate reflux symptoms. Monitoring for signs of esophageal injury through endoscopic procedures is essential in patients with advanced liver disease, as early identification of esophagitis allows for prompt treatment and prevents further complications.

One of the most serious and life-threatening complications associated with GERD in liver disease patients is variceal bleeding. Esophageal varices, which are dilated blood vessels in the esophagus caused by portal hypertension, are common in patients with cirrhosis. These varices are at risk of rupture, leading to severe bleeding. GERD symptoms, especially when untreated, can worsen the risk of variceal bleeding, as the acid reflux may contribute to additional irritation of the varices, increasing the likelihood of rupture.

Preventing variceal bleeding requires a two-pronged approach: managing the underlying liver disease and treating GERD effectively. The management of portal hypertension through non-selective beta-blockers, such as propranolol, is a cornerstone of preventing variceal bleeding. These medications reduce the pressure within the portal venous system, thus lowering the risk of variceal rupture. Additionally, patients with liver cirrhosis should undergo regular screening for esophageal varices through endoscopic procedures to detect varices early and assess their risk of bleeding. In cases where varices are detected, prophylactic banding or sclerotherapy may be performed to prevent bleeding episodes.

From a GERD management perspective, controlling acid reflux with PPIs helps minimize the irritation of varices and reduces the risk of bleeding(Wolfe & Sachs, 2000). However, it is crucial to note that in patients with cirrhosis and ascites, PPIs should be used with caution due to the potential for renal impairment and electrolyte imbalances. Therefore, careful monitoring of kidney function is essential when prescribing these medications.

The severity of liver disease plays a significant role in treatment decisions for GERD, esophagitis, and variceal bleeding. As liver disease progresses, the risk of developing these complications increases. For example, patients with decompensated cirrhosis (Child-Pugh Class C) have a much higher risk of variceal bleeding, making strict control of portal hypertension critical. In such patients, the use of beta-blockers should be coupled with careful monitoring for signs of variceal rupture or bleeding, with the addition of endoscopic banding as needed.

Furthermore, advanced liver disease may complicate the pharmacological management of GERD. Since patients with cirrhosis often have impaired liver function, the metabolism and clearance of certain drugs may be altered, necessitating dose adjustments. For instance, when prescribing PPIs, healthcare providers must be cautious about drug interactions and side effects, particularly regarding renal function and electrolyte levels.

A multidisciplinary approach is crucial for guiding treatment decisions and preventing complications in hepatic patients with GERD. Collaboration between hepatologists, gastroenterologists, dietitians, and other healthcare providers ensures that both the liver disease and its associated gastrointestinal complications are managed comprehensively. Regular follow-ups with a healthcare team are essential for monitoring liver function, gastrointestinal symptoms, and potential complications like esophagitis and variceal bleeding. This team-based approach also allows for early detection and intervention, reducing the risk of severe outcomes.

4. CONCLUSION

This research sheds light on the significant relationship between GERD incidence and liver disease, particularly chronic hepatitis and decompensated liver cirrhosis, using the GERD-Q questionnaire as a diagnostic tool. The findings emphasize that patients with liver diseases, especially those with decompensated cirrhosis, exhibit higher GERD incidence rates, which in turn complicate their overall clinical management. The study highlights the importance of early detection and appropriate management of GERD in hepatic patients, underscoring the role of the GERD-Q as a reliable tool for diagnosing and monitoring symptoms. The results of this study contribute to a deeper understanding of the symptom burden faced by patients with liver disease, emphasizing the need for tailored treatment strategies that address both GERD and the underlying liver condition. Effective management of GERD in these patients not only alleviates discomfort but also plays a crucial role in preventing severe complications such as esophagitis and variceal bleeding, which can significantly worsen patient outcomes. Ultimately, this research advocates for a multidisciplinary approach to care, where healthcare providers ranging from hepatologists to gastroenterologists work collaboratively to optimize treatment decisions, minimize complications, and improve the quality of life for patients with chronic liver disease. By incorporating the findings of this study into clinical practice, healthcare professionals can provide more personalized and effective interventions, ultimately leading to better patient management and outcomes in those suffering from both GERD and liver disease.

REFERENCES

AB AZIZ, N. I. B. (2016). *PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AMONG PATIENTS IN KLINIK*. UNIVERSITI SAINS MALAYSIA.

Cassel, C. K., Leipzig, R. M., Cohen, H. J., Larson, E. B., Meier, D. E., Capello, C. F., & Wilson, J. A. P. (2003). Gastroenterologic disorders. *Geriatric Medicine: An Evidence-Based Approach*, 835–851.

Cho, J. H., Song, D. J., Kang, J. Bin, Lee, D. H., Jin, S., Zhang, C., Zhang, Y., Feng, Z., Zhang, F., & Liu, Z. (n.d.). *IP-3_G T he P revalenceof N ontuberculous Mycobacterial Lung Disease with or without Reflux Esophagitis Seoul National University, Bundang Hospital*.

Chunlertrith, K., Noiprasit, A., Foocharoen, C., Mairiang, P., Sukeepaisarnjaroen, W., Sangchan, A., & Sawadpanitch, K. (2014). GERD questionnaire for diagnosis of gastroesophageal reflux disease in systemic sclerosis. *Clin Exp Rheumatol*, *32*(Suppl 86), 98–102.

Commisso, A., & Lim, F. (2019). Lifestyle modifications in adults and older adults with chronic gastroesophageal reflux disease (GERD). *Critical Care Nursing Quarterly*, *42*(1), 64–74.

Emmanuel, A., & Inns, S. (2011). *Gastroenterology and hepatology*. John Wiley & Sons.

Gill, K., Ghazinian, H., Manch, R., & Gish, R. (2016). Hepatitis C virus as a systemic disease: reaching beyond the liver. *Hepatology International*, *10*, 415–423.

Jones, R. T. (2016). *Clinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis*. Newcastle University.

Kahrilas, P. J. (2003). GERD pathogenesis, pathophysiology, and clinical manifestations. *Cleveland Clinic Journal of Medicine*, *70*(5), S4.

Kaltenbach, T., Crockett, S., & Gerson, L. B. (2006). Are lifestyle measures effective in patients with gastroesophageal reflux disease?: an evidence-based approach. *Archives of Internal Medicine*, *166*(9), 965–971.

Katzka, D. A., & Kahrilas, P. J. (2020). Advances in the diagnosis and management of gastroesophageal reflux disease. *Bmj*, *371*.

Khalaf, M., Castell, D., & Elias, P. S. (2020). Spectrum of esophageal motility disorders in patients with liver cirrhosis. *World Journal of Hepatology*, *12*(12), 1158.

Kim, W. O. (2012). Institutional review board (IRB) and ethical issues in clinical research. *Korean Journal of Anesthesiology*, *62*(1), 3.

Li, D., Sedano, S., Allen, R., Gong, J., Cho, M., & Sharma, S. (2019). Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. *Cancers*, *11*(6), 841.

Okushin, K., Takahashi, Y., Yamamichi, N., Shimamoto, T., Enooku, K., Fujinaga, H., Tsutsumi, T., Shintani, Y., Sakaguchi, Y., & Ono, S. (2015). Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. *BMC Gastroenterology*, *15*, 1–10.

Roehlen, N., Crouchet, E., & Baumert, T. F. (2020). Liver fibrosis: mechanistic concepts and therapeutic perspectives. *Cells*, *9*(4), 875.

Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013). Beyond scoring: a modern interpretation of disease progression in chronic liver disease. *Gut*, *62*(9), 1234–1241.

Rudralingam, V., Footitt, C., & Layton, B. (2017). Ascites matters. *Ultrasound*, *25*(2), 69–79.

Saberifiroozi, M. (2017). Improving quality of care in patients with liver cirrhosis. *Middle East Journal of Digestive Diseases*, *9*(4), 189.

Samonakis, D. N., Koulentaki, M., Coucoutsi, C., Augoustaki, A., Baritaki, C., Digenakis, E., Papiamonis, N., Fragaki, M., Matrella, E., & Tzardi, M. (2014). Clinical outcomes of compensated and decompensated cirrhosis: A long term study. *World Journal of Hepatology*, *6*(7), 504.

Shaheen, N. J., Hansen, R. A., Morgan, D. R., Gangarosa, L. M., Ringel, Y., Thiny, M. T., Russo, M. W., & Sandler, R. S. (2006). The burden of gastrointestinal and liver diseases, 2006. *Official Journal of the American College of Gastroenterology| ACG*, *101*(9), 2128–2138.

Spechler, S. J. (2013). Barrett esophagus and risk of esophageal cancer: a clinical review. *Jama*, *310*(6).

Strobl, J., Cave, E., & Walley, T. (2000). Data protection legislation: interpretation and barriers to research. *Bmj*, *321*(7265), 890–892.

Wijarnpreecha, K., Panjawatanan, P., Thongprayoon, C., Jaruvongvanich, V., & Ungprasert, P. (2017). Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. *Saudi Journal of Gastroenterology*, *23*(6), 311–317.

Wolfe, M. M., & Sachs, G. (2000). Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. *Gastroenterology*, *118*(2), S9–S31.

Yuksel, E. S., & Vaezi, M. (2012). Extraesophageal manifestations of gastroesophageal reflux disease: cough, asthma, laryngitis, chest pain. *Swiss Medical Weekly*, *142*(1112), w13544–w13544.